“Prompt appellate review is necessary to address a controlling question of law that could obviate the need for prolonged, costly, and complex litigation, and resolve industry-wide uncertainty,” the company wrote in its Nov. 22 motion.
Both proposed antitrust class actions accuse Takeda of bottlenecking the generic approval process by gaming the Hatch-Waxman Act, which awards six months of generic exclusivity to companies that get brand-name ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.